CLINICAL_TRIALS
trial_result
· 2021-11-18
Clinical Trial Update: Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
Summary
Phase 2 results update for a therapy intended to reduce autoantibodies in patients with idiopathic pulmonary fibrosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: University of Alabama at Birmingham | Conditions: Ambulatory IPF | Phase 2 | Status: COMPLETED | Results posted: 2021-11-18